Head­ed for a block­buster smash, Roche picks up an­oth­er key OK for land­mark MS drug Ocre­vus

Roche’s quest to make its pi­o­neer­ing MS drug Ocre­vus in­to a multi­bil­lion-dol­lar block­buster has gath­ered some added steam with an EU mar­ket­ing ap­proval — 9 months af­ter the big FDA green light came through.

An­a­lysts ex­pect that Ocre­vus can rack up $3 bil­lion in peak sales, with the phar­ma gi­ant rolling up not that far from $1 bil­lion in just the first 9 months in the US. That’s ex­act­ly the kind of block­buster smash that Roche needs now as fran­chise drugs like Rit­ux­an, Her­ceptin and Avastin are shred­ded by gener­ic ri­vals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.